This was a multicenter randomized phase III study. Random assignment was performed at the time of surgery in cases with residual tumor ≤0.25 cm. HIPEC with cisplatin (CDDP) 75 mg/m 2 for 60 minutes at ...

Background: Although immunotherapy has changed the treatment strategy for many cancers with great success, patients with microsatellite stable (MSS) and RAS-mutant metastatic colorectal cancer (mCRC) ...

Individual patient data from 20 randomized multicenter trials were collected. Eleven studies (4,773 patients) with sufficient data were analyzed to evaluate whether 9- or 12-month MRD-CR classified at ...

Our previous NECO phase II studies on high-grade osteosarcoma suggested that administering ifosfamide (IF; 16 g/m 2 [4g/m 2 once on day 1, then 2g/m 2 once on days 2-7] × six) to patients showing a ...

Cancer treatment has evolved significantly, with a growing recognition that high-quality care extends beyond treating the disease alone. Multiple guidelines emphasize the need for comprehensive person ...

Risk of non-breast cancer–related mortality in breast cancer and dependence on disease characteristics, treatment, and survival duration. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus–Initiated Oropharynx Cancer Despite ...

Background: NIVO + RELA fixed-dose combination (FDC), compared with NIVO alone, demonstrated a clinically meaningful benefit to progression-free survival (HR 0.79, 95% CI 0.66–0.95) and overall ...

Hepatocellular carcinoma (HCC) is a lethal malignancy that is subtle neither in its clinical presentation nor in its aggressive course. Numerous diagnostic guidelines have focused on noninvasive ...

MCARH109 is a first-in-class G protein–coupled receptor, class C, group 5, member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed/refractory multiple ...

With that background, Birken et al 5 aimed to better understand the interplay between oncology and primary care in the follow-up of cancer survivors. The authors mined their electronic health record ...

Background: Neutropenia is the most common hematological toxicity of myelosuppressive chemotherapy. To observe the efficacy and safety of efbemalenograstim alfa in the prevention of absolute ...